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This study was to determine the impact of adjunctive Buchang Naoxintong Jiaonang (BNJ) to clopidogrel on volunteers with
the CYP2C19∗2 gene mutation accompanied with qi deﬁciency and blood stasis (QDBS) constitution. Eighteen males with
QDBS constitution were selected, who were 6 CYP2C19∗1/∗1, 6 CYP2C19∗1/∗2, and 6 CYP2C19∗2/∗2, and signed informed
consent. Results showed that the maximal platelet aggregation (Aggmax) and 5min aggregation (Agglate)w i t h5 - µmol/L ADP in
three diﬀerent CYP2C19∗2 genotypes were signiﬁcantly decreased after any drug therapy compared with corresponding baseline
measurements (all values P<. 05). But percent inhibitions of Aggmax and Agglate (IPAs) in CYP2C19∗2/∗2g e n o t y p ea t4h o u r s ,
24 hours, 3 days, and 7 days after clopidogrel administration were all the lowest among three CYP2C19∗2 genotypes (P<. 01),
andIPAsinCYP2C19∗1/∗2 genotype were between CYP2C19∗1/∗1andCYP2C19∗2/∗2.IPAshadnosigniﬁcantdiﬀerence among
three diﬀerent CYP2C19∗2genotypes afterBNJoradjunctive BNJ.Inaddition,changesofCD62P,PAC1,andsCD40Lweresimilar
to changes of ADP-induced platelet aggregation in three diﬀerent CYP2C19∗2 genotypes. Conclusion was that adjunctive BNJ to
clopidogrel can enhance the antiplatelet eﬀect in volunteers with the CYP2C19∗2g e n em u t a t i o n .
1.Introduction
The recent USFoodand DrugAdministration (FDA)“boxed
warning” on clopidogrel is based on the concern that
the antiplatelet eﬀect of clopidogrel depends primarily on
its activation by the cytochrome P450 (CYP) system [1].
Patients with decreased CYP2C19 function because of
genetic polymorphisms metabolize clopidogrel poorly and
have higher rates of cardiovascular events after acute coro-
nary syndrome (ACS) and percutaneous coronary interven-
t i o n s( P C I s )t h a np a t i e n t sw ith normal CYP2C19 function
[2, 3]. CYP2C19∗2 is the most common genetic vari-
ant reproducibly associated with variability in clopidogrel
active metabolite bioavailability, antiplatelet eﬀects, and
clinical outcomes [4, 5]. To overcome deﬁcits in clopidogrel
responsiveness, one approach is to increase the dose of
clopidogrel [6, 7]. Other strategy is to add a third drug
(such as Cilostazol) to aspirin and clopidogrel to further
enhance platelet inhibition [8]. The other approach is to
substitute a newer, more potent platelet inhibitor drug (such
as prasugrel) for clopidogrel [9]. However, these strategies
that enhanced response to clopidogrel are often associated
with a higher risk for bleeding that may be attributed to
the overmuch inhibition of the TXA2 and ADP platelet
activation pathways that are essential for normal hemostasis
[10,11].Theseconsiderationsunderscoretheneedforagents
that providemore comprehensiveplatelet inhibition without
interfering with hemostasis, for greater protection against
thrombotic events with no incremental bleeding risk. In
traditional Chinese medicine (TCM), it is expressed by2 Evidence-Based Complementary and Alternative Medicine
regulating theyin and yang balance [12], by applying holistic
approaches to enhance the system’s harmony, a method
called dual regulation.
Qideﬁciencyandbloodstasissyndrome isthemostcom-
mon syndrome in patients with coronary heart disease,
especially after PCI [13, 14]. Buyang Huanwu decoction
(BYHWD), a TCM formula, has been recognized as a
treatment for coronary heart diseases with Qi deﬁciency
and blood stasis syndrome and cerebrovascular diseases in
clinic [15]. Buchang Naoxintong Jiaonang (BNJ) consists of
BYHWD plus Scorpio and Hirudo. Therefore, it was a
compound preparation of BYHWD. BNJ is an approved
TCM for stroke [16], which is widely used, and is well
tolerated. BNJ combined with aspirin could enhance the
antiplatelet eﬀect in patients with cardio-cerebrovascular
diseases [17].
The purpose of this study was to determine the impact
of adjunctive BNJ in volunteers with the CYP2C19∗2g e n e
mutation accompanied with qi deﬁciency and blood stasis
constitution during treatment of clopidogrel.
2.Methods
2.1. Subject Population. Male volunteers were eligible for
enrollment if they were between 25 and 55 years of age,
undergoing medical examination in Fujian Provincial Hos-
pital, and identiﬁed as having genotype CYP2C19∗2. Based
on the theory of constitution of TCM [18, 19], qi deﬁciency
constitution and blood stasis (or stagnant blood) consti-
tution were evaluated. Qi deﬁciency constitution means
insuﬃciency of primordial QI; lassitude, short breath, and
spontaneous perspiration are its main characteristics. Blood
stasis constitution means an impeded blood ﬂow; dark
or purplish tongue and complexion are its main charac-
teristics. Major exclusion criteria included active bleeding
and bleeding diatheses, any antiplatelet or anticoagulation
therapy, contraindication to antiplatelet therapy, leukocyte
count <3.0 × 109/L, platelet count100.0< × 109/L,aspartate
aminotransferase oralanineaminotransferase levels>3times
upper normal, serum creatinine level >2.5mg/dL, having no
histories such as cardiovascular or cerebral vessels diseases,
diabetes, phlebothrombosis, arterial thrombus, gastritis,
peptic ulcer, hepatitis, cholecystitis, renal disease, neoplastic
disease, external injury or operationwithin 6 months, inabil-
ity to follow the protocol. The Institutional Review Board
of Provincial Clinical College of Fujian Medical University
approved the study protocol, and the patients provided
written informed consent for participation. The study was
performed in the Clinical Pharmacological Base of Fujian
Provincial Hospital. CYP2C19∗2 genotyping, adenosine
diphosphate- (ADP-) induced platelet aggregation, enzyme
immunoassays, and ﬂow cytometry were ﬁnished in Fujian
Provincial Key Laboratory of cardiovascular disease and
Fujian Provincial Clinical Laboratory, respectively.
2.2. Genotyping by TaqMan Polymerase Chain Reaction
(PCR). GenomicDNAwasextractedfrom200µLperipheral
potassium ethylenediaminetetraacetic acid-anticoagulated
blood with the TIANamp Blood DNA Kit {TIANGEN
BIOTECH (BEIJING) CO., LTD} according to the manu-
facturer’s instruction. CYP2C19∗2 (681G > A; rs4244285)
was genotyped using polymerase chain reaction and
restriction fragment length polymorphism (PCR-RFLP).
MultiGene Gradient Thermal Cycler (TC9600-G-230V,
Labnet International, Inc.) was selected. PCR was per-
formed in a 25µL reaction mixture containing 1.0µL
of DNA, 0.8µL of each primer (forward primer 5 -
CAGAGCTTGGCATATTGTATC-3  and reverse primer
5 -GTAAACACACAACTAGTCAATG-3 ), 2.0µLo fe a c h
dNTPs, 2.5µLo f1 0r e a c t i o nb u ﬀer, 17.6µLo fs t e r i l i z i n g ,
and 0.3µL of Taq DNA polymerase (Xiamen Tagege
Biotechnology Co., Ltd.). PCR parameters consisted of an
initial denaturation for 5min at 94◦C, followed by 35 cycles
of 30s at 94◦C, 20s at 56◦C, and 20s at 72◦C, and by a
ﬁnal extension for 5min at 72◦C. The PCR product was
then digested with SmaI (Xiamen Tagege Biotechnology
Co., Ltd.) for 5-6 hours at 30◦C yielding 2 fragments of
212 and 109bp in the case of the GG genotype. For the AA
genotype a single band of 321bp was observed. For the GA
genotype 3 fragments of 321, 212, and 109bp were observed.
Genotypes were directly observed with an ImageMaster
VDS-CL (Amersham Pharmacia Co., Sweden) and were
conﬁrmed with ABI 3700 Automated DNA Sequencer.
PCR-RFLP was performed to genotype CYP2C19∗2 in 360
medical examination male volunteers aged 25–55. There
were 204 subjects with CYP2C19∗1/∗1(681GG) genotype,
127 subjects with CYP2C19∗1/∗2(681GA) genotype and 24
subjects with CYP2C19∗2/∗2(681AA) genotype.
2.3. Study Design. The ABNJC-CYP2C19∗2( A d j u n c t i v e
Buchang Naoxintong Jiaonang versus Clopidogrel in Volun-
teers with CYP2C19∗2 Gene Mutation) study is a prospec-
tive, controlled platelet function study of CYP2C19∗2G e n e
Mutation in Volunteers with Qi Deﬁciency and Blood Stasis
Constitution. The ﬂow diagram of the study is depicted
in Figure 1. Eighteen male volunteers with qi deﬁciency
and blood stasis constitution were selected, who were 6
CYP2C19∗1/∗1, 6 CYP2C19∗1/∗2, and 6 CYP2C19∗2/∗2,
and signed informed consent. All subjects have stopped
taking any medicine two weeks before the study. There were
no cigarette smoking, no drinking alcohol, and no drinking
coﬀeeduringthestudy.Eachsubjecttookclopidogrel300mg
o nt h eﬁ r s td a ya n dt h e n7 5m go n c ed a i l yf o rc o n s e c u t i v e
six days. After seven washing days, BNJ (0.8g thrice per
day)wastakenforﬁvedays.ThenBNJ-combinedclopidogrel
were taken for 7 days (the dose was the same as above).
BNJ (Naoxintong) 0.4g capsules (Compilation of The
National Standard of Chinese Traditional Medicine no. WS-
10001 (ZD-0001)-2002; Med-drug Permit no. Z20025001)
were supplied by the Buchang Pharmaceutical Co., Ltd.,
and Plavix (clopidogrel bisulfate) 75mg tablets (Med-drug
Permit no. J20080090) were provided by Sanoﬁ-Winthrop
Industrie. The test, dispensing, and records were taken by
GCP (good clinical practice) trained doctor. Venous blood
samples were drawn by trained nurses. Blood samples were
obtained to measure the ADP-induced platelet aggregation
by turbidimetry at baseline and 4 hours, 24 hours, 3
days and 7 days after clopidogrel administration, 7 daysEvidence-Based Complementary and Alternative Medicine 3
CYP2C19∗1/∗1( n = 6) CYP2C19∗1/∗2( n = 6) CYP2C19∗2/∗2( n = 6)
Genotype CYP2C19∗2 was performed in medical
examination male volunteers (n = 360)
Clopidogrel 300mg on the ﬁrst day and then 75mg once daily
for consecutive six days after signing informed consent
Baseline
4 hours
3d a y s
7d a y s
Washing for 7 days 14 days
BNJ 0.8g, tid for 5 days 19 days











Figure 1: Study protocol timeline. The ﬁgure shows the ABNJC-CYP2C19∗2 trial protocol.
after washing, 5 days after BNJ administration, and 7 days
after BNJ combined clopidogrel, and measure the platelet
count, platelet functional (ADP-induced platelet aggrega-
tion, Platelet activation of the membrane marker P-selectin
(CD62p), and Platelet Activator combined-l (PAC-1) with
ﬂow cytometry) and inﬂammatory index (Soluble CD40L
(sCD40L) with enzyme-linked Immunosorbent assay) at
baseline, 7 days after clopidogrel administration, 5 days after
BNJadministration, and7daysafterBNJ-combinedclopido-
grel, respectively. Hemoglobin (Hb), Platelet count, fasting
plasma glucose (FSG), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), plasma total cholesterol
(TC), and plasma creatinine (Cr) were remeasured at
baseline and the end of the test, respectively. Creatinine
clearance rate (CGCCr) was calculated by Cockcroft/Gault
formula: CGCCr = (140-age)∗(Wt in kg)∗(0.85 if female)/
(72∗Cr).
2.4. Adenosine Diphosphate-Induced Platelet Aggregation.
Aggregation studies were performed within 2 hours after
blood collection, at 37◦C, by using a turbidimetric method
of Born [20] on an LBY-NJ4-channel platelet aggregation
analyzer (Beijing Precil Instrument Co., Ltd). The whole
blood was centrifuged at 700rpm for 4min to prepare
platelet-rich plasma (PRP).The remaining bloodwas further
centrifuged at 3500rpm for 10min to prepare platelet-poor
plasma (PPP). The platelet counts of PRP were adjusted
to 200 × 109/L. Results were recorded as light transmission
at maximal aggregation (Aggmax) and 5min aggregation
(Agglate) after the addition of ADP (SIGMA-ALORICH)
at ﬁnal concentrations of 5µmol/L. Aggmax is considered
to reﬂect the activity of both P2Y1 and P2Y12 receptors,
whereas Agglate is more reﬂective of P2Y12 receptor activity.
Inhibition of platelet aggregation (IPA) was deﬁned as the
percent decrease of aggregation values (Aggmax and Agglate)
between baseline and after treatment and calculated as
follows: IPA (%) = ([intensity of aggregation at baseline −
intensity of aggregation after treatment]/[intensity of aggre-
gation at baseline]) × 100 [8]. Percentage of platelet dis-
aggregation between Aggmax and Agglate was deﬁned as fol-
lows: disaggregation (%) = ([Aggmax− Agglate]/[Aggmax]) ×
100 [8].4 Evidence-Based Complementary and Alternative Medicine
2.5. Flow Cytometry. All ﬂow cytometric studies were con-
ducted on Beckman Coulter Epics XL Flow Cytometer
(Becton Dickinson, America) using CellQuest software
(Becton Dickinson) for data acquisition and analysis.
Analyses were performed on citrated whole blood diluted
1:9 in phosphate-buﬀered saline incubated with either
PAC-1 ﬂuorescein isothiocyanate-conjugated monoclonal
antibody (Becton Dickinson) and anti-P-selectin (CD62p)
phycoerythrin-conjugated monoclonal antibody (Becton
Dickinson). Platelet activation markers (CD62p and PAC-1)
were measured in unstimulated platelets and after stimula-
tion of platelets with ADP (5µmol/L ﬁnal concentration).
2.6. Enzyme Immunoassays (EIAs). Serum levels of Soluble
CD40 ligand (sCD40L, R&D Systems Inc., America) were
determined by EIA (detection limit, 0.03ng/mL; Bender
Medsystems, Vienna, Austria) according to the manufac-
turer’s instructions (intra- and interassay coeﬃcient of
variation <10%). Analysis was performed in duplicates in
a blinded fashion. All samples from a given patient were
analyzed inthesame microtiterplatetominimize run-to-run
variability.
2.7. Statistical Analysis. Data were analyzed using SPSS
(version 13.0, SPSS Inc., America) and expressed as mean
and SD. A paired samples t-test was used to make pairwise
comparisons between baseline and each of treatment at each
time point. The eﬀects of adjunctive BNJ versus clopidogrel
on platelet count, inhibition of platelet aggregation, platelet
disaggregation, plateletactivation, and inﬂammation marker
in the three CYP2C19 genotype groups were compared by
an analysis of variance. Multiple comparisons used LSD or
Tamhane. A value of P<. 05 was considered to indicate
statistical signiﬁcance.
3.Results
3.1. Subjects Characteristics. Baseline BP, BMI, Hb, platelet
count, blood biochemical indicators, and CYP2C19∗2g e n o -
types were performed in 360 medical examination male
volunteers. Eighteen male volunteers with qi deﬁciency
and blood stasis constitution were selected, who were 6
CYP2C19∗1/∗1, 6 CYP2C19∗1/∗2, and 6 CYP2C19∗2/∗2
(Table 1). At baseline there were no signiﬁcant diﬀerence
in platelet count, Aggmax and Agglate with 5-µmol/L ADP
stimuli, CD62P, PAC-1, and sCD40L among three diﬀerent
CYP2C19∗2 genotypes (Tables 2 and 3).
All subjects completed the treatment allocated in the
study protocol. All treatments were well tolerated, and
no subject discontinued the study drugs. Compared with
baseline, Hb, platelet count, blood biochemical indicators
at the end of the test had no signiﬁcant diﬀerence in
three diﬀerent CYP2C19∗2 genotypes, except for CGCCr in
CYP2C19∗1/∗1 genotype (Tables 3 and 4).
3.2. ADP-Induced Platelet Aggregation. The results of a
paired samples t-test showed that subjects in three diﬀerent




















































4h 24h 3 d 7 d 19 d 26 d
∗ CYP2C19 1/∗1( n = 6)
CYP2C19∗1/∗2( n = 6)










46.5 ± 15.6 48.1 ± 16.9 45.9 ± 14.4 48.1 ± 16.9 66.1 ± 8.8 64.4 ± 8.5
15.6 ± 4.7 13.6 ± 8.6 12 ± 7.6 13.6 ± 8.6 62.5 ± 6.7 66.2 ± 3
P value
61.3 ± 7.5 62.9 ± 5.9 59.5 ± 7.6 62.9 ± 5.9 68 ± 4.2 67.7 ± 2.7
<0.001 <0.001 <0.001 <0.001 <0.404 <0.573
Figure 2:Inhibitionofmaximalplatelet aggregation with5-µmol/L
ADP between baseline and after therapy among the three CYP2C19
genotypes. The points represent the mean platelet inhibition. Bars
indicate standard deviations. 4h, 24h, 3d, and 7d was after
clopidogrel therapy. 19d was 5 days after BNJ administration. 26d
was 7 days after adjunctive BNJ. The P values are the results of the
one-wayanalysisofvariance.“∗”symbolexpresses thattheP values
are for comparison to CYP2C19∗1/∗1 in LSD or Tamhane. ∗, ∗∗,
∗∗∗ ,represent P<. 05, <.01, and <.001, respectively; “+” symbol
expresses that the P values are for comparisonto CYP2C19∗1/∗2i n
LSD or Tamhane; +, ++, +++ represent P<. 05, <. 01, and <. 001,
respectively.
Aggmax after any drug (clopidogrel or BNJ or adjunctive
BNJ) administration compared with corresponding baseline
measurements (all values P<. 05). But the Aggmax 7dafter
washing in CYP2C19∗1/∗1 and CYP2C192/∗2 genotypes
were signiﬁcantly higher than those at baseline, except for
Aggmax in CYP2C19∗1/∗2 genotype. Aggmax values after BNJ
or adjunctive BNJ clopidogrel therapy in three diﬀerent
CYP2C19∗2 genotypes were signiﬁcantly lower than those
7d a y sa f t e rw a s h i n g( Table 2, all values P<. 01). On the
other hand, the results of an analysis of variance found that
IPAs of Aggmax with 5-µm o l / LA D Ps t i m u l ia t4h o u r s ,2 4
hours, 3 days, and 7 days after clopidogrel administration
in CYP2C19∗2/∗2 genotype were all much lower than
those in CYP2C19∗1/∗1g e n o t y p e( Figure 2,a l lv a l u e sP<
.01), and IPAs of Aggmax with 5-µmol/L ADP stimuli in
CYP2C19∗1/∗2 genotype were between CYP2C19∗1/∗1a n d
CYP2C19∗2/∗2( Figure 2). IPAs of Aggmax with 5-µmol/L
ADP stimuli 5 days after BNJ administration or 7 days
afterBNJ-combinedclopidogrelhadnosigniﬁcantdiﬀerence
among three diﬀerent CYP2C19∗2 genotypes.
Signiﬁcant reductions in Agglate after any drug (clopido-
grel or BNJ or adjunctive BNJ clopidogrel) administration
were also observed in three diﬀerent CYP2C19∗2 genotypes,
compared with their corresponding baseline measurements
(all values P<. 05). Likewise, Agglate 7d a y sa f t e rw a s h i n g
in CYP2C19∗1/∗1 and CYP2C192/∗2 genotypes were signif-
icantly higher than those at baseline, except for Agglate inEvidence-Based Complementary and Alternative Medicine 5
























1 33 21.8 130/70 134.0 257.0 4.93 92.1 36.6 38.6 5.3 CYP2C19∗1/∗1
2 36 21.0 118/70 136.0 204.0 5.19 89.3 33.3 37.3 5.0 CYP2C19∗1/∗1
3 38 19.8 118/80 153.0 295.0 4.69 87.6 38.7 38.9 5.4 CYP2C19∗1/∗1
4 48 22.1 120/70 152.0 189.0 4.69 88.2 34.6 36.4 5.2 CYP2C19∗1/∗1
5 35 21.7 110/70 167.0 240.0 4.68 90.2 33.2 33.3 4.1 CYP2C19∗1/∗1
6 36 24.5 102/80 125.0 231.0 4.96 84.6 37.8 38.7 4.6 CYP2C19∗1/∗1
7 42 22.8 120/80 126.0 269.0 6.33 87.5 32.9 39.2 5.4 CYP2C19∗1/∗2
8 35 23.9 116/70 135.0 273.0 4.88 91.6 39.6 37.7 3.6 CYP2C19∗1/∗2
9 32 21.3 120/80 154.0 271.0 5.44 92.3 33.7 38.1 5.6 CYP2C19∗1/∗2
10 34 23.5 106/74 133.0 218.0 6.96 111.6 36.5 38.8 5.0 CYP2C19∗1/∗2
11 34 20.1 108/70 164.0 217.0 4.68 119.8 37.9 36.7 3.4 CYP2C19∗1/∗2
12 37 23.4 120/80 156.0 298.0 4.48 116.6 38.8 37.7 4.1 CYP2C19∗1/∗2
13 36 18.4 120/80 153.0 288.0 4.98 87.9 38.1 37.3 3.9 CYP2C19∗2/∗2
14 43 21.1 120/70 152.0 293.0 6.6 86.3 40.0 39.4 3.9 CYP2C19∗2/∗2
15 45 24.2 124/84 145.0 298 5.39 87.7 38.2 39.0 5.2 CYP2C19∗2/∗2
16 35 21.6 100/70 139.0 217 5.55 102.3 36.9 34.6 4.3 CYP2C19∗2/∗2
17 41 20.6 108/84 149.0 203 4.19 106.6 37.5 35.7 4.2 CYP2C19∗2/∗2
18 39 23.1 116/80 145.0 284 5.32 95.4 36.7 37.5 5.1 CYP2C19∗2/∗2











CYP2C19∗1/∗1( n = 6)
CYP2C19∗1/∗2( n = 6)
CYP2C19∗2/∗2( n = 6)







































62.2 ± 7.4 64.2 ± 2.8 64 ± 6.3 64 ± 6.2 68 ± 4.2 69 ± 2.7
45.7 ± 16.6 47.4 ± 14.2 47.6 ± 17.8 47.6 ± 17.6 66.1 ± 8.9 65.7 ± 9.2












<0.001 <0.001 <0.001 <0.001 <0.384 <0.62
Figure 3: Inhibition of late platelet aggregation with 5-µmol/L
ADP between baseline and after therapy among the three CYP2C19
genotypes. The points represent the mean platelet inhibition; bars
indicate standard deviations. P values and symbol as in Figure 2.
CYP2C19∗1/∗2g e n o t y p e( Table 2). Agglate values in three
diﬀerent CYP2C19∗2 genotypes were signiﬁcantly diﬀerent
between 7 days after washing and 5 days after BNJ or 7 days
after adjunctive BNJ clopidogrel therapy (Table 2, all values
P<. 01). IPAs of Agglate with ADP stimulus are illustrated in
Figure 3.IP A sofA gg late were similar toIPA of Aggmax with5-









































14 d 4h 0h 24h 3d 7d 19d 26d
2.1 ± 0.9 4.3 ± 1.1 4.2 ± 1.5 5.1 ± 0.9 5.2 ± 0.7 1.4 ± 0.3 4.9 ± 0.85.3 ± 0.7
3.9 ± 1.9 2.8 ± 0.8 3.7 ± 1.1 3.5 ± 1.4 3.3 ± 0.6 2.4 ± 0.7 5.1 ± 0.66.4 ± 2.5
2.9 ± 1.3 1.4 ± 0.5 1.9 ± 0.9 2.5 ± 0.7 2.3 ± 0.7 1.9 ± 0.7 4.4 ± 1.75.2 ± 0.7







∗∗ ∗∗ + +
<0.001 <0.001
Figure 4: Platelet disaggregation with 5-µmol/L ADP between
baseline and after therapy among the three CYP2C19 genotypes.
The points represent the mean platelet inhibition; bars indicate
standard deviations. 0h was at baseline. 14d was 7 days after
washing. The others as in Figure 2.
Baseline percentages of platelet disaggregation with 5-
µm o l / LA D Ps t i m u l ih a dn os i g n i ﬁ c a n td i ﬀerence among
three diﬀerent CYP2C19∗2 genotypes. After clopidogrel
therapy, percentages of platelet disaggregation were signif-
icantly diﬀerent in three diﬀerent CYP2C19∗2 genotypes
(Figure 4). The platelet disaggregation at 4 hours, 24 hours,
3 days, and 7 days after clopidogrel therapy was the
lowest in CYP2C19∗2/∗2 genotype, compared with their
corresponding clopidogrel therapy in CYP2C19∗1/∗1a n d
CYP2C19∗1/∗2 genotypes (all values; P<. 05). The
platelet disaggregation in CYP2C191/∗2g e n o t y p ew a s
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Platelet count (× 109/L)
CYP2C19∗1/∗1( n = 6) 236.0 ±37.9 228.7 ±42.60 .172 239.7 ±35.5 .315 224.7 ±30.0 .093
CYP2C19∗1/∗2( n = 6) 257.7 ±32.85 253.5 ±33.8 .627 251.3 ±21.2 .474 254.2 ±30.0 .489
CYP2C19∗2/∗2( n = 6) 263.8 ±42.2 266.7 ±26.6 .890 234.8 ±52.5 .037 245.0 ±29.6 .085
CD62P platelet positive (%)
CYP2C19∗1/∗1( n = 6) 38.6 ± 2.72 7 .0 ±2.6 .001 26.9 ±2.1 .001 26.0 ± 2.8 .001
CYP2C19∗1/∗2( n = 6) 38.8 ± 1.93 2 .6 ±1.7 <.001 27.0 ±2.2 <.001 26.2 ± 2.6 <.001
CYP2C19∗2/∗2( n = 6) 38.4 ± 1.93 6 .6 ±2.0 .001 26.7 ±1.9 <.001 22.2 ± 1.1 <.001
PAC-1 platelet positive (%)
CYP2C19∗1/∗1( n = 6) 40.6 ± 4.92 8 .1 ±2.6 <.001 25.9 ±4.6 <.001 25.3 ± 4.5 <.001
CYP2C19∗1/∗2( n = 6) 40.0 ± 2.33 5 .9 ±1.9 <.001 29.9 ±2.2 <.001 23.4 ± 0.7 <.001
CYP2C19∗2/∗2( n = 6) 38.1 ± 3.23 4 .9 ±2.0 <.001 27.3 ±3.4 <.001 20.4 ± 1.2 <.001
Inﬂammatory marker
sCD40L (ng/mL)
CYP2C19∗1/∗1( n = 6) 3.3 ± 0.91 .3 ±0.3 .001 1.9 ±0.7 .001 1.2 ± 0.3 .001
CYP2C19∗1/∗2( n = 6) 3.2 ± 0.72 .2 ±0.4 .002 2.2 ±0.4 .002 1.3 ± 0.3 .001
CYP2C19∗2/∗2( n = 6) 3.1 ± 0.22 .6 ±0.5 .007 2.4 ±0.4 .007 1.2 ± 0.3 <.001
Note: values are presented as mean ± SD. The P values are for comparison to baseline. CD62p: platelet activation of the membrane marker P-selectin; PAC-1:
antibody against activated glycoprotein IIb/IIIa; sCD40L: soluble CD40L.
Table 4: Characteristics of three diﬀerent CYP2C19∗2 genotyped subjects at baseline and the end of the test.
CYP2C19∗1/∗1( n = 6) P value CYP2C19∗1/∗2( n = 6) P value CYP2C19∗2/∗2( n = 6)
P value
Baseline The end Baseline The end Baseline The end
Hb (g/L) 144.5± 15.5 145.7 ±13.6 .428 144.7 ±15.3 144.7 ±16.3 1.000 147.2± 5.2 150 ±6.9 .467
FSG (mmol/L) 4.9 ±0.25 .1 ±0.6 .722 5.5 ±1.05 .2 ±1.3 .437 5.3 ±0.85 .3 ± 0.7 1.000
ALT (µ/L) 37.2 ± 2.13 7 .2 ±2.3 1.000 38.0 ±0.93 7 .0 ±3.3 .414 37.3 ±1.93 7 .2 ±1.2 .921
AST (µ/L) 35.7 ± 2.33 6 .3 ±2.8 .171 36.6 ±2.73 6 .7 ±1.8 .855 37.9 ±1.23 6 .8 ±2.4 .309
CGCCr
(ml/min) 88.67 ± 2.5 101.6 ±9.9 .017 103.2 ±14.39 2 .0 ±4.3 .099 94.4 ±8.58 8 .5 ±5.5 .060
TC (mmol/L) 4.9 ±0.54 .8 ± 0.6 .782 4.5 ±0.94 .6 ±0.7 .472 4.4 ±0.64 .2 ±0.5 .398
Note: values are presented as mean ± SD. The P values are for comparison to baseline.
7 days after washing, percentages of platelet disaggrega-
tion in CYP2C191/∗2 genotype was higher than those in
CYP2C19∗1/∗1g e n o t y p e( P<. 05). Percentages of platelet
disaggregation 5 days after BNJ administration or 7 days
afterBNJ-combinedclopidogrelhadnosigniﬁcantdiﬀerence
among three diﬀerent CYP2C19∗2 genotypes (Figure 4).
3.3. Platelet Count, Platelet Activation, and Inﬂammation.
There were no signiﬁcant diﬀerences in platelet count
after treatment compared with corresponding baseline mea-
surements, except for subjects in CYP2C19∗2/∗2g e n o t y p e
(Table 3). Changes of platelet count were not signiﬁcantly
diﬀerent among three CYP2C19∗2 genotypes (Figure 5).
CD62P, PAC1, and sCD40L were signiﬁcantly reduced after
clopidogrel administration or adjunctive BNJ-compared
with corresponding baseline measurements (P<. 01). After
BNJ or BNJ combined clopidogrel, changes of these param-
eters were similar to changes of ADP-induced platelet aggre-
gation in three diﬀerent CYP2C19∗2 genotypes (Figure 5).
4.Discussion
This ABNJC-CYP2C19∗2 study is the ﬁrst to demonstrate
that adjunctive BNJ to clopidogrel can intensify platelet
inhibition in volunteerswith the CYP2C19∗2g e n em u t a t i o n
including heterozygous (CYP2C19∗1/∗2) and homozygous
for mutations (CYP2C19∗2/∗2 ) .F u r t h e r m o r e ,t h i ss t u d y
showed that adjunctive BNJ as compared with clopidogrel of
75mg/dayresultedinlessplateletaggregationinCYP2C19∗2
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Figure 5: Eﬀects of adjunctive naoxintong versus clopidogrel on platelet count (a), platelet activation (b, c), and inﬂammation (d) among
the three CYP2C19 genotypes. The points represent the mean platelet inhibition; bars indicate standard deviations. P values and symbol as
in Figure 2.
studies to assess whether adjunctive BNJ, as compared
with other intensiﬁed regimens, provides long-term clinical
beneﬁts in patients with CYP2C19∗2g e n em u t a t i o n .
CYP2C19 plays an important role in the bioactivation of
clopidogrel. The CYP2C19∗2 allele is one of the mutations
responsible for the phenotype known as poor clopidogrel
metabolizer. The genetic polymorphism has been associated
with a poor response to clopidogrel in healthy volunteers
[21]. The clinical eﬃcacy data mirror the eﬀect of genetic
polymorphisms on platelet function in both heterozygotes
as well as homozygotes. Carriers of a CYP2C19∗2 allele
have been found to have an absolute reduction in platelet
aggregation in response to clopidogrel that was 9 percentage
points less than that of noncarriers [22]. In addition,
medications metabolized by CYP450, such as omeprazole
(an inhibitor of CYP2C19), have been shown to inﬂuence
clopidogrel eﬀect. Omeprazole has been associated with
al o w e re ﬃcacy of clopidogrel as assessed by the platelet
reactivity index vasoactive-stimulated phosphoprotein [23].
TCM is an essential part of the health care system in
several Asian countries and is considered a complementary
or alternative medical system in most Western countries.
Researchers are going to pay close attention to the regulation
of Chinese materia medica on cytochrome P450 system [24].
Chan et al. [25] suggest that the interactions between Clopi-
dogrel and Angelica dahurica or Ginkgo biloba or Scutellaria
baicalensis can inhibit activities of CYP2C9 enzymes.
The ingredients of BNJ include Radix Astragali, Radix
Angelicae Sinensis, Radix Paeoniae Rubra, Radix Salviae
Miltiorrhizae, Rhizoma Chuanxiong, Semen Persicae, Flos
Carthami, Resina Olibani, Myrrha, Caulis Spatholobi, Radix
Achyranthis Bidentatae, Ramulus Cinnamomi, Ramulus
Mori, Pheretima, Scorpio, and Hirudo. Wang’s studies
observed that Astragalus saponins are the essential compo-
nent of BNJ conﬁrmed by HPLC-MS [26]. The regulation
of Astragalus saponins on cytochrome P450 system has
not been reported. Xia’s studies showed that Angelica
sinensis Polysaccharides can modulate the activities ofEvidence-Based Complementary and Alternative Medicine 9
drug metabolism enzymes [27]. In our study, we observe
that adjunctive BNJ can overcome an attenuation of the
antiplatelet eﬀect of clopidogrel in volunteers with the
CYP2C19∗2 gene mutation accompanied with qi deﬁciency
and blood stasis constitution as demonstrated by all aggre-
gometric and ﬂow cytometric parameters obtained. Further
researches should be undertaken to determine which ingre-
dient or constituents of BNJ are with potential of CPY2C19
modulation.
4.1.StudyLimitations. Althoughprospective,ourstudypop-
ulation is small, and they are not patients. Due to the
diﬃculties in identifying the active constituents responsible
for the modulation of CPY2C19 enzyme, prediction of BNJ-
clopidogrel metabolic interactions is diﬃcult.
5.Conclusions
Among volunteers with the CYP2C19∗2g e n em u t a t i o n
accompanied with qi deﬁciency and blood stasis constitu-
tion, adjunctive BNJ achieves intensiﬁed platelet inhibition
as compared with clopidogrel of 75mg/day. It needs to
be evaluated whether the therapy could be translated into
improved clinical outcomes.
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